Gastrointestinal stromal tumor
Second line
Gastrointestinal stromal tumor (GIST) in adults after progression on imatinib or imatinib intolerance. Per ESMO 2022 and SEOM 2023 – second-line. Dose: 50 mg orally once daily on the 4/2 schedule or 37.5 mg continuous daily dosing. Efficacy depends on KIT/PDGFRA mutation subtype.
Sources